Addressing Limited Treatment Options for Refractory CRC
Written by
Cancer Network
Published
0
comments
0
min
The phase 2 INTERCEPT-TT trial showed that TAS-102 induced ctDNA clearance following adjuvant chemotherapy in patients with colorectal cancer.